Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden
Scandinavian Journal of Infectious Diseases · 2012-11 · 44 (11) · 852-859
DOI: 10.3109/00365548.2012.689847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Infectious Diseases, online erschienen am 17.07.2012. Verfasst von Kerstin Malm und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden. kerstin.malm@orebroll.se. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Prevalence data on human T-lymphotropic virus types 1 and 2 (HTLV-1/2) in Sweden have not been updated since 1995. The seroprevalence among blood donors at that time was 0.2/10,000. A few years earlier, a high prevalence of HTLV-2 was found in intravenous drug users (IDUs) in Stockholm (3.4%). The objective of this study was to update information on the seroprevalence of HTLV in several study groups. METHODS: Serum samples from pregnant women, hepatitis C virus (HCV)-positive individuals, and IDUs in Stockholm were investigated for HTLV-1/2 antibodies. Data from the mandatory HTLV-1/2 screening (2003-2006) of in vitro fertilization (IVF) clients were compiled, as well as data from new blood donors. RESULTS: Eight out of 35,000 IVF patients were positive for anti-HTLV-1/2 (seroprevalence 2.3 per 10,000). Of the anti-HCV-positive individuals (n = 355), 1 sample was HTLV-1-positive (28.2 per 10,000). From 1995 to 2007, 18 HTLV-positive new blood donors were identified out of approximately 550,000 individuals tested (0.3 per 10,000). Thirty-five of 1079 tested IDUs were screening reactive. CONCLUSIONS: Since the start of screening in 1994, there has been no increased seroprevalence of HTLV-1/2 among blood donors in Sweden. Seroprevalence among Swedish IVF patients is 10 times higher than among blood donors. This finding is comparable to a 2003 European seroprevalence study of pregnant women in 7 countries. However, the possibility that the IVF group includes individuals with a higher risk of acquiring sexually transmitted infections, including HTLV, than the general population cannot be ruled out.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden. kerstin.malm@orebroll.se
Zitieren
APA
Malm, K., Ekermo, B., Hillgren, K., Britton, S., Fredlund, H., & Andersson, S. (2012). Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden. Scandinavian Journal of Infectious Diseases, 44(11), 852-859. https://doi.org/10.3109/00365548.2012.689847
Vancouver
Malm K, Ekermo B, Hillgren K, Britton S, Fredlund H, Andersson S. Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden. Scandinavian Journal of Infectious Diseases. 2012;44(11):852-859. doi:10.3109/00365548.2012.689847
BibTeX
@article{Malm2012,
author = {Malm, Kerstin and Ekermo, Bengt and Hillgren, Kristina and Britton, Sven and Fredlund, Hans and Andersson, Sören},
title = {Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden},
journal = {Scandinavian Journal of Infectious Diseases},
year = {2012},
volume = {44},
number = {11},
pages = {852--859},
doi = {10.3109/00365548.2012.689847}
}
EUVIMED